Un appel de demandes est en cours pour le fonds Pilote

 À propos d’INOVAIT

Established in 2020, INOVAIT is the pan-Canadian network dedicated to developing and commercializing advanced image-guided therapy (IGT) technologies. The network invests strategically in collaborative partnerships that build upon Canada’s strength in digital innovation and medical science research to create a critical mass of world-leading IGT companies. The network brings together small, medium-sized, and large companies, research organizations, post-secondary institutions, and not-for-profit organizations to bolster the Canadian IGT sector and poise it to become leaders on the global stage. The network is hosted by Sunnybrook Research Institute and supported by the Government of Canada’s Strategic Innovation Fund.

Nous souhaitons que le Canada soit le siège d’un écosystème de thérapie guidée par imagerie véritablement intégré qui favorise l’innovation continue et révolutionne les soins de santé à l’échelle mondiale.

Nous mission consiste à établir des liens, à former et à investir au profit des plus brillants cerveaux et des initiatives les plus prometteuses du secteur en vue d’améliorer les résultats pour les patients et de favoriser le développement économique au Canada.

INOVAIT est fier d’avoir été fondé par l’Institut de recherche Sunnybrook (IRS), la division de recherche du Centre des sciences de la santé Sunnybrook — l’un des plus importants centres universitaires de sciences de la santé au Canada, entièrement affilié à l’Université de Toronto. L’IRS accueille le Centre de recherche en thérapie guidée par imagerie qui met au point des méthodes inédites ou améliorées pour détecter, diagnostiquer et traiter des problèmes de santé complexes. En outre, Sunnybrook a été reconnu comme étant un centre d’excellence par la Focused Ultrasound Foundation, le premier site au Canada — et l’un des sept au monde — à recevoir cet honneur.

Grâce à l’offre exceptionnelle

d’INOVAIT, le réseau pourra :

  • Investir dans l’intégration de l’IA et des appareils de TGI
  • Renforcer les collaborations en R et D entre des laboratoires de recherche de calibre mondial, de jeunes pousses, des PME et des multinationales
  • Former du personnel hautement qualifié
?

Ce qui permettra de faire ce qui suit :

  • Accroître l’investissement privé dans la TGI
  • Favoriser la croissance de l’industrie, mesurée par l’augmentation du nombre d’entreprises, d’emplois et des ventes
  • Affermir la réputation scientifique, clinique et commerciale du Canada dans le domaine de la TGI
?

Et finalement,

  • Améliorer les résultats des patients
  • Réduire les coûts des soins de santé
  • Stimuler le développement économique

Conseil d’administration

Le conseil d’administration est responsable de la gouvernance globale du réseau et se compose de membres éminents issus des communautés des affaires, de la science, de la recherche et de la technologie.

Dr. M. Cynthia Goh, PhD and Professor of Chemistry at University of Toronto
Université de Toronto

M Cynthia Goh

Dr. Steven Beyea, PhD and Scientific Director of the Biomedical Translational Imaging Centre
IWK & Nova Scotia Health Authorities

Steven Beyea

Linda Brown, a self-employed consultant

Linda Brown

INOVAIT Co-Executive Director and VP Research and Innovation at Sunnybrook Research Institute

Kullervo Hynynen

Cara Ferreira headshot
Executive at Fusion Pharmaceuticals

Cara Ferreira

Université de Toronto

M Cynthia Goh

La professeure Cynthia Goh, Ph.D., enseigne la chimie à l’Université de Toronto; c’est une entrepreneure accomplie dont l’objectif est de transposer les connaissances scientifiques en produits utiles pour la société. En plus d’avoir fondé sept entreprises à caractère scientifique, elle a aussi élaboré et mis en œuvre des programmes de formation comme Techno et entrepreneuriat 101 (E101 au Centre MaRS).

IWK & Nova Scotia Health Authorities

Steven Beyea

Le professeur Steven Beyea, Ph.D., est directeur scientifique du Biomedical Translational Imaging Centre, un établissement de recherche situé dans les centres de santé IWK et QEII à Halifax (Nouvelle-Écosse). Il se penche sur l’imagerie médicale dans plusieurs sphères : recherche universitaire, application clinique, et partenariat et commercialisation avec l’industrie. En outre, il enseigne au département de radiologie de l’Université Dalhousie, ainsi qu’aux départements de sciences de la santé, de génie biomédical et de physique.

Linda Brown

Linda Brown est une experte-conseil indépendante qui met à profit son expérience internationale dans les soins de santé, ses pratiques exemplaires en matière de processus d’affaires, et son leadership en marketing et en ventes pour aider les jeunes entreprises à commercialiser leurs technologies et leurs solutions. Linda a travaillé chez Siemens Healthcare pendant plus de 20 ans en tant que cadre supérieur à des postes de gestion des ventes et de marketing à l’échelle nationale et internationale.

INOVAIT Co-Executive Director and VP Research and Innovation at Sunnybrook Research Institute

Kullervo Hynynen

Dr. Kullervo Hynynen, Ph.D., is Vice President of Research and Innovation and a senior scientist at Sunnybrook Research Institute (SRI), a professor in the Department of Biophysics at the University of Toronto, and is a world leader in focused ultrasound research with over 500 scientific papers and about 30 issued or pending patents. Throughout his career, he has built various networks and consortia on focused ultrasound research and commercial development. His work has led to the creation of four companies – Insightec, Ultradiagnostics, Arrayus, and FUS instruments – and as Vice President of Research and Innovation and earlier as the Physical Sciences Platform Director at SRI, he has played a key managerial role in developing SRI commercial activity, including 17 start-ups in the last 13 years.

Executive at Fusion Pharmaceuticals

Cara Ferreira

Dr. Cara Ferreira, PhD, MBA, is an executive at Fusion Pharmaceuticals a clinical stage company focused on targeted alpha therapy for cancer treatment. Previously, Cara was an Associate Partner at McKinsey & Company, where she led strategy consulting for global pharmaceutical and medical device clients. She is recognized as an inclusive leader and an outstanding mentor in both the business and scientific communities.

Équipe de direction

L’équipe d’INOVAIT veille à l’exploitation continue et au succès du réseau de la thérapie guidée par imagerie et de l’intelligence artificielle.

Raphael Ronen, MSc, CFA, Director, Commercialization and Administration, INOVAIT
INOVAIT Co-Executive Director

Raphael Ronen

Headshot of Ahmed Nasef.
Gestionnaire de programmes

Ahmed Nasef

Leo Mui's headshot
Gestionnaire du financement

Leo Mui

Administrative Assistant

Teresa Bellantone

Project Officer

Kristian Hau

Finance Analyst

Mandy Ho

Amar Gill headshot
Legal Counsel

Amar Gill

Communications Strategist

Clara MacKinnon-Cabral

Philip Boyer's headshot
Project Analyst

Philip Boyer

INOVAIT Co-Executive Director

Raphael Ronen

Raphael Ronen, M.Sc., CFA, has over 17 years in the medical device industry, with wide-ranging experience in business development and commercialization, including product development, financing, technology assessment, licensing, and IP management. For the past 10 years, he has had increasing managerial positions in technology transfer and business development with various world-renowned academic institutions, including MaRS Innovation, University of Toronto, and Robarts Research Institute. Most recently, he serves as Director, Business Development at Sunnybrook Research Institute. Raphael has also held senior management and advisory positions within several emerging Canadian image-guided therapy companies, including FUS Instruments and Harmonic Medical. Throughout his career, Raphael has raised over $75M in grants for commercialization activities for several industry and academic partners across Canada, including the previous FedDev TDP and ICP awards to SRI, bringing together 28 industry and academic partners to advance IGT technologies. Raphael holds a Chartered Financial Analyst (CFA) designation, an M.Sc. in Medical Biophysics from the University of Western Ontario, and a B.Sc. in Systems Design Engineering from the University of Waterloo.

Gestionnaire de programmes

Ahmed Nasef

Ahmed Nasef, MD, MBA manages INOVAIT’s networking, outreach and training programs. Ahmed is an enthusiastic clinician entrepreneur who brings more than 11 years of lived experience in healthcare innovation, health science research, and technology commercialization. Ahmed holds an Adjunct Lecturer appointment at the Department of Medical Biophysics at the University of Toronto, and has been managing Medventions, Sunnybrook’s flagship healthcare innovation training program. Ahmed earned his MD degree from Cairo, Egypt and holds an MBA in healthcare management and technology innovation from Schulich School of Business at York University.

Gestionnaire du financement

Leo Mui

Leo Mui, MSc gère le programme de financement d’INOVAIT pour la recherche collaborative et la commercialisation; il travaille en étroite collaboration avec l’industrie et le milieu universitaire pour créer et soutenir des projets importants dans le domaine des TGI et de l’IA. Au cours de sa carrière, il a occupé divers rôles visant à rapprocher la science et la société grâce à l’entrepreneuriat et à la commercialisation. Leo est titulaire d’une maîtrise en chimie organique de l’Université de Toronto et d’un baccalauréat en chimie et en géographie humaine.

Administrative Assistant

Teresa Bellantone

Teresa Bellantone is an Administrative Assistant with the INOVAIT team, supporting Raphael Ronen. She is excited to be a part of a growing network that provides the opportunity to do interesting, complex work that’s meaningful to the lives of all. She has a varied background supporting senior management in the mining, asset management and hydro utility businesses.

Project Officer

Kristian Hau

Kristian Hau, MBIOT, conducts project-related tasks for INOVAIT’s funding program by working closely with Network participants, from application submissions to facilitating reviews and reporting. He has held an assortment of positions during his career – from scientific research labs in academia and industry, to business development role in biotech startups. Kristian obtained his Master of Biotechnology from the University of Guelph after completing a bachelor’s degree in biochemistry at the University of Waterloo.

Finance Analyst

Mandy Ho

Mandy Ho, BA, assists network members with their financial questions pertaining to their projects and providing guidance during the claims process involving both the government and INOVAIT. Her educational background includes a Bachelor of Business Administration from the University of Guelph and a Diploma in Business Administration with a specialization in accounting from Humber College. She is actively pursuing CPA certification.

Legal Counsel

Amar Gill

Amar Gill, H.Bcom, JD, assists with the drafting and negotiation of legal agreements along with ad-hoc legal matters relating to INOVAIT. Amar also supports Sunnybrook Health Sciences Centre’s legal services team, working primarily on research agreements. Amar has an honours degree in business commerce, specializing in accounting.

Communications Strategist

Clara MacKinnon-Cabral

Clara MacKinnon-Cabral, HBSc, leads INOVAIT’s marketing, events, and public relations efforts. While raising awareness about INOVAIT’s tremendous role in Canada’s image-guided therapy sector, she assists members in marketing strategy. She has a Bachelor of Science from the University of Toronto, specializing in neuroscience, psychology, and art history. Clara’s extensive interdisciplinary background in art and science has equipped her with a robust health communications skill set.

Project Analyst

Philip Boyer

Phil Boyer, MASc, PhD, enables INOVAIT’s data strategy by supporting the network’s health data working group and is leading efforts to define the Canadian IGT sector through market research with input from network member companies. Phil has a strong background in both research and commercialization, having completed his PhD work at Sunnybrook Research Institute and previously serving various roles at a national centre for the commercialization of medical devices. Phil has a PhD in biomedical engineering from the University of Toronto, a Masters of Applied Science in biomedical engineering from Carleton University, and a bachelor’s degree in aerospace engineering from Carleton University.